WallStSmart

Ciena Corp (CIEN)vsPfizer Inc (PFE)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Pfizer Inc generates 1136% more annual revenue ($63.32B vs $5.12B). PFE leads profitability with a 11.8% profit margin vs 4.5%. CIEN appears more attractively valued with a PEG of 2.27. PFE earns a higher WallStSmart Score of 55/100 (C).

CIEN

Buy

52

out of 100

Grade: C-

Growth: 8.7Profit: 5.5Value: 3.7Quality: 6.5
Piotroski: 6/9Altman Z: 1.18

PFE

Buy

55

out of 100

Grade: C

Growth: 3.3Profit: 7.0Value: 6.0Quality: 4.8
Piotroski: 3/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for CIEN.

PFEUndervalued (+31.4%)

Margin of Safety

+31.4%

Fair Value

$37.44

Current Price

$25.68

$11.76 discount

UndervaluedFair: $37.44Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CIEN3 strengths · Avg: 9.7/10
Revenue GrowthGrowth
33.1%10/10

Revenue surging 33.1% year-over-year

EPS GrowthGrowth
232.3%10/10

Earnings expanding 232.3% YoY

Market CapQuality
$76.18B9/10

Large-cap with strong market position

PFE4 strengths · Avg: 8.8/10
Operating MarginProfitability
31.6%10/10

Strong operational efficiency at 31.6%

Market CapQuality
$150.92B9/10

Large-cap with strong market position

Price/BookValuation
1.7x8/10

Reasonable price relative to book value

Free Cash FlowQuality
$2.18B8/10

Generating 2.2B in free cash flow

Areas to Watch

CIEN4 concerns · Avg: 2.8/10
PEG RatioValuation
2.274/10

Expensive relative to growth rate

Profit MarginProfitability
4.5%3/10

4.5% margin — thin

P/E RatioValuation
345.4x2/10

Premium valuation, high expectations priced in

Price/BookValuation
27.8x2/10

Trading at 27.8x book value

PFE3 concerns · Avg: 2.3/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
13.772/10

Expensive relative to growth rate

EPS GrowthGrowth
-10.1%2/10

Earnings declined 10.1%

Comparative Analysis Report

WallStSmart Research

Bull Case : CIEN

The strongest argument for CIEN centers on Revenue Growth, EPS Growth, Market Cap. Revenue growth of 33.1% demonstrates continued momentum.

Bull Case : PFE

The strongest argument for PFE centers on Operating Margin, Market Cap, Price/Book.

Bear Case : CIEN

The primary concerns for CIEN are PEG Ratio, Profit Margin, P/E Ratio. A P/E of 345.4x leaves little room for execution misses. Thin 4.5% margins leave little buffer for downturns.

Bear Case : PFE

The primary concerns for PFE are Piotroski F-Score, PEG Ratio, EPS Growth.

Key Dynamics to Monitor

CIEN profiles as a hypergrowth stock while PFE is a value play — different risk/reward profiles.

CIEN carries more volatility with a beta of 1.25 — expect wider price swings.

CIEN is growing revenue faster at 33.1% — sustainability is the question.

PFE generates stronger free cash flow (2.2B), providing more financial flexibility.

Bottom Line

PFE scores higher overall (55/100 vs 52/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Ciena Corp

TECHNOLOGY · COMMUNICATION EQUIPMENT · USA

Ciena Corporation provides hardware, software, and network services that support the transport, routing, switching, aggregation, service delivery, and management of video, data, and voice traffic on communications networks worldwide. The company is headquartered in Hanover, Maryland.

Visit Website →

Pfizer Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered on 42nd Street in Manhattan, New York City. The name of the company commemorates its co-founder, Charles Pfizer (1824-1906). Pfizer develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology. The company has several blockbuster drugs or products that each generate more than 1 billion USD in annual revenues.

Visit Website →

Want to dig deeper into these stocks?